{"version":"1.0","type":"link","title":"Impact of first-line dual immuno-oncology combination therapy versus immuno-oncology plus tyrosine kinase inhibitor on outcomes of second-line VEGFR-TKI in advanced RCC: a real-world multi-institutional analysis.","author_name":"Nishimura K 외","author_url":"https://prs-insight.online/author/Nishimura%20K","provider_name":"PRSinsight","provider_url":"https://prs-insight.online","thumbnail_url":"https://prs-insight.online/og/paper/168064","thumbnail_width":1200,"thumbnail_height":630}